South San Francisco, CA — September 28, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved 75 mg/0.5 mL and 150 mg/1 mL single-dose prefilled…Original Article
FDA Approves Genentech’s Xolair (omalizumab) Prefilled Syringe Formulation
